Latest Biotech News

Rocket Pharmaceuticals received FDA approval for Kresladi, its gene therapy for leukocyte-adhesion deficiency type 1 (LAD1), an ultra-rare inherited immunodeficiency that can be fatal in infants...

United Therapeutics’ Tyvaso cleared another key late-stage milestone in idiopathic pulmonary fibrosis after a second Phase III trial hit its endpoints. The company is positioning for a potential...

Memorial Sloan Kettering researchers engineered a new uPAR-directed CAR T-cell therapy intended to expand cell therapy targeting beyond conventional antigens in solid tumors. The work centers on...

Novartis moved to expand its allergy and immunology pipeline by acquiring Excellergy. The purchase targets Exl-111, an anti-IgE antibody currently in Phase I testing, with potential applications...

Viridian Therapeutics disclosed top-line Phase III results for elegrobart (VRDN-003), an insulin-like growth factor 1 receptor (IGF-1R) monoclonal antibody in active thyroid eye disease. Patients...

Roche secured FDA 510(k) clearance for two Cobas Pro Integrated Solutions lab automation units—Cobas c 703 and Cobas ISE Neo—aimed at increasing throughput and reducing workflow friction in...

Canada’s PhenoTips partnered with five clinical institutions to launch the CIPHER network, an initiative funded with C$5.4 million from Genome Canada to accelerate AI genomic medicine. The program...

ICON teamed with Advarra to create an integrated, AI-driven site network model aimed at reducing clinical trial start-up delays. The partnership connects ICON’s trial services operations with...

Kailera Therapeutics moved to the public markets, filing plans for an IPO to fund its obesity portfolio, led by weekly GLP-1/GIP agonist ribupatide (KAI-9531). The Boston-based biotech, backed by...

Eli Lilly expanded its AI drug discovery collaboration with Insilico Medicine, signing a deal that could total $2.75 billion in development, regulatory, and commercial milestones. Lilly will pay...

Washington University School of Medicine in St. Louis announced that the U.S. FDA granted Breakthrough Therapy Designation to a CAR-T cell treatment targeting uPAR for solid tumors. The therapy...

Novartis agreed to acquire Excellergy, adding an anti-IgE antibody program (Exl-111) currently in Phase I testing. The deal broadens Novartis’ immune and inflammation pipeline, with Exl-111...

ICON partnered with institutional review board and clinical trial management provider Advarra to build an integrated, AI-driven clinical site network model aimed at speeding study startup. The...

Takeda announced plans to lay off nearly 250 workers at its Cambridge, Massachusetts site, beginning in July, after a board-approved cost-saving plan approved March 25. The workforce reduction is...

Viridian Therapeutics disclosed topline Phase 3 results for elegrobart (formerly VRDN-003) in active thyroid eye disease, reporting that the subcutaneous, half-life-extended IGF-1R antibody met a...

United Therapeutics said its second Phase 3 trial of Tyvaso (treprostinil) for idiopathic pulmonary fibrosis met endpoints, strengthening the company’s case for a supplemental NDA and potential...

Boston Scientific presented data from the Champion-AF trial showing that Watchman FLX provided superior protection from bleeding compared with non-vitamin K oral anticoagulants in atrial...

Blackstone announced it closed its Blackstone Life Sciences VI fund at $6.3 billion, the largest life sciences private investment vehicle it has raised. The new fund is nearly 40% larger than the...

Rocket Pharmaceuticals secured FDA approval for Kresladi, its gene therapy for leukocyte-adhesion deficiency type 1 (LAD-1). The company said the approval makes Kresladi the first gene therapy...

United Therapeutics’ Tyvaso (treprostinil) hit endpoints in a second phase 3 idiopathic pulmonary fibrosis (IPF) study, strengthening its case for a supplemental NDA review. The trial reportedly...